Important Safety Information

  • The most common adverse reactions in clinical studies (≥ 3% of Aimovig-treated patients and more often than placebo) were injection site reactions and constipation.

Please see Aimovig full Prescribing Information.


Indication

Aimovig is indicated for the preventive treatment of migraine in adults.

Aimovig —a therapy specifically designed to help prevent migraine1

Aimovig selectively targets and blocks the calcitonin gene-related peptide receptor (CGRP-R), disrupting a key component of migraine pathophysiology1-6

The CGRP neuropeptide activates the CGRP-R3,4,7-9

CGRP-R is located at sites that are relevant to migraine pathophysiology.

Graphic representation of Aimovig™ (erenumab-aooe) blocking the CGRP-receptor.

The activation of CGRP-Rs is believed to contribute to migraine10,11

Levels of CGRP have been shown to increase during a migraine attack.

Graphic representation of Aimovig™ (erenumab-aooe) blocking the CGRP-receptor.

Aimovig targets and blocks the CGRP-R5

Aimovig is a 100% human monoclonal antibody that binds potently and selectively to the CGRP-R to inhibit its function.


Aimovig is available for once-monthly
self-administration with the SureClick® autoinjector1


See how Aimovig disrupts migraine pathophysiology1

Clinical Data

Indication

Aimovig is indicated for the preventive treatment of migraine in adults.

Important Safety Information

Please see Aimovig full Prescribing Information.

References: 1. Aimovig™ (erenumab-aooe) prescribing information, Amgen. 2. Burstein R, Noseda R, Borsook D. Migraine: Multiple processes, complex pathophysiology. J Neurosci. 2015;35(17):6619-6629. 3. Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015;80(2):193-199. 4. Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533-552. 5. Shi L, Lehto SG, Zhu DX, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against calcitonin gene-related peptide receptor. J Pharmacol Ex Ther. 2016;356:223-231. 6. Vu T, Ma P, Chen JS, et al. Pharmacokinetic-pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy migraine subjects. Pharm Res. 2017;34:1784-1795. 7. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553-622. 8. Raddant AC, Russo AF. Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med. 2011;13:e36. 9. Walker CS, Hay DL. CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors? Br J Pharmacol. 2013;170:1293-1307. 10. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183-187. 11. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48-56.